{
    "nct_id": "NCT03033303",
    "official_title": "Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study",
    "inclusion_criteria": "* Diagnosis of NB as defined by a) histopathology (confirmed by the MSK Department of Pathology), or b) BM metastases or MIBG-avid lesion(s) plus high urine catecholamine levels.\n* Patients must have high-risk NB (MYCN-amplified stage 2/3/4/4S of any age and MYCN-nonamplified stage 4 in patients greater than 18 months of age).\n* Patients must be in first CR/VGPR\n* Patients must have a negative human anti-hu3F8 antibody (HAHA) titer\nHealthy volunteers allowed",
    "exclusion_criteria": "* Existing major organ dysfunction, i.e., renal., cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity â‰¥ grade 3, with the exception of hearing loss and hematologic toxicity.\n* Active life-threatening infection.\n* Inability to comply with protocol requirements",
    "miscellaneous_criteria": ""
}